How does the Q2 revenue compare to the company’s historical revenue trends?

RenovoRx’s Q2‑2025 revenue of just over $400 k is modest in absolute terms but, for a biotech that has historically generated only pocket‑size cash flows from its FDA‑cleared RenovoCath device, it represents a meaningful upward tick. The company’s prior quarterly disclosures have typically shown “commercial revenue” in the low‑to‑mid six‑figure range, and in some earlier periods the line item was essentially zero as the device rollout was still in its infancy. In that context, breaking the $400 k threshold signals that the commercial rollout is gaining traction and that the market is beginning to respond to the clinical need the company highlights.

From a trading standpoint, the revenue uplift dovetails with the positive Independent Data Monitoring Committee recommendation for the TIGeR‑PaC Phase III trial—both catalysts could tighten the risk‑reward profile. Technically, RNXT has been hovering near its 50‑day moving average with modest upside volume; a breach above the recent resistance (~$6.50) on sustained buying could push the stock toward its prior high‑quarterly range (~$8). Conversely, any failure to translate this early revenue growth into broader market adoption or a delay in trial read‑outs could see the price retest the 200‑day moving average (~$5) and test support around the $4.50‑$5.00 band. For risk‑averse traders, a small‑position “buy‑the‑dip” near $5 with a stop just below $4.70 may capture upside if the rollout accelerates, while more defensive players might wait for a clearer trend confirmation after the next earnings release.